Immutep Ltd (IMM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immutep Ltd (IMM) has a cash flow conversion efficiency ratio of -0.233x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-33.50 Million ≈ $-23.71 Million USD) by net assets (AU$143.64 Million ≈ $101.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immutep Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Immutep Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IMM current and long-term liabilities for a breakdown of total debt and financial obligations.
Immutep Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immutep Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Garo AB
ST:GARO
|
0.070x |
|
Manba Finance Ltd
NSE:MANBA
|
N/A |
|
Scherzer & Co. AG
F:PZS
|
N/A |
|
Chemfab Alkalis Limited
NSE:CHEMFAB
|
0.030x |
|
CTCBIO Inc
KQ:060590
|
0.079x |
|
Cobre Ltd
AU:CBE
|
-0.030x |
|
PJ Metal Co. Ltd
KQ:128660
|
-0.274x |
|
THINKWARE Corporation
KQ:084730
|
0.070x |
Annual Cash Flow Conversion Efficiency for Immutep Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Immutep Ltd from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see IMM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$143.64 Million ≈ $101.63 Million |
AU$-62.05 Million ≈ $-43.90 Million |
-0.432x | -135.12% |
| 2024-06-30 | AU$189.52 Million ≈ $134.10 Million |
AU$-34.82 Million ≈ $-24.64 Million |
-0.184x | +30.12% |
| 2023-06-30 | AU$136.47 Million ≈ $96.56 Million |
AU$-35.88 Million ≈ $-25.39 Million |
-0.263x | +18.17% |
| 2022-06-30 | AU$94.08 Million ≈ $66.57 Million |
AU$-30.23 Million ≈ $-21.39 Million |
-0.321x | -33.47% |
| 2021-06-30 | AU$73.27 Million ≈ $51.84 Million |
AU$-17.64 Million ≈ $-12.48 Million |
-0.241x | +26.04% |
| 2020-06-30 | AU$33.30 Million ≈ $23.56 Million |
AU$-10.84 Million ≈ $-7.67 Million |
-0.326x | +48.07% |
| 2019-06-30 | AU$24.39 Million ≈ $17.26 Million |
AU$-15.29 Million ≈ $-10.82 Million |
-0.627x | -176573.57% |
| 2018-06-30 | AU$33.52 Million ≈ $23.72 Million |
AU$-11.89K ≈ $-8.42K |
0.000x | +99.89% |
| 2017-06-30 | AU$26.53 Million ≈ $18.77 Million |
AU$-8.51 Million ≈ $-6.02 Million |
-0.321x | -0.12% |
| 2016-06-30 | AU$35.32 Million ≈ $24.99 Million |
AU$-11.31 Million ≈ $-8.00 Million |
-0.320x | -1.53% |
| 2015-06-30 | AU$24.69 Million ≈ $17.47 Million |
AU$-7.79 Million ≈ $-5.51 Million |
-0.315x | +49.92% |
| 2014-06-30 | AU$22.59 Million ≈ $15.99 Million |
AU$-14.23 Million ≈ $-10.07 Million |
-0.630x | -14.85% |
| 2013-06-30 | AU$29.25 Million ≈ $20.70 Million |
AU$-16.04 Million ≈ $-11.35 Million |
-0.548x | -6.56% |
| 2012-06-30 | AU$37.16 Million ≈ $26.29 Million |
AU$-19.12 Million ≈ $-13.53 Million |
-0.515x | -190.62% |
| 2011-06-30 | AU$55.10 Million ≈ $38.99 Million |
AU$-9.76 Million ≈ $-6.90 Million |
-0.177x | +54.00% |
| 2010-06-30 | AU$16.79 Million ≈ $11.88 Million |
AU$-6.46 Million ≈ $-4.57 Million |
-0.385x | +62.96% |
| 2009-06-30 | AU$1.81 Million ≈ $1.28 Million |
AU$-1.88 Million ≈ $-1.33 Million |
-1.039x | -76.06% |
| 2008-06-30 | AU$2.63 Million ≈ $1.86 Million |
AU$-1.55 Million ≈ $-1.10 Million |
-0.590x | +27.67% |
| 2007-06-30 | AU$4.08 Million ≈ $2.89 Million |
AU$-3.33 Million ≈ $-2.36 Million |
-0.816x | -2.03% |
| 2006-06-30 | AU$6.32 Million ≈ $4.47 Million |
AU$-5.05 Million ≈ $-3.57 Million |
-0.800x | -40.92% |
| 2005-06-30 | AU$8.34 Million ≈ $5.90 Million |
AU$-4.73 Million ≈ $-3.35 Million |
-0.568x | +48.43% |
| 2004-06-30 | AU$5.13 Million ≈ $3.63 Million |
AU$-5.64 Million ≈ $-3.99 Million |
-1.100x | -- |
About Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more